NCPA is skeptical that Express Scripts, owned by Cigna, will walk the walk on its recent announcement that it plans to evolve the one-sided business relationship PBMs exploit that results in decreased transparency, higher patient prescription drug costs, and stifled competition. Based on past actions by Cigna-Express Scripts, NCPA believes there is no basis for independent pharmacies to have confidence they will actually see increased reimbursements from Cigna-Express Scripts. Learn why ahead of this week’s Hill meetings.
NCPA
